The reduction in the price target from $26 to $14 by a reputable analyst firm like Piper Sandler could lead to a negative short-term sentiment among investors, potentially causing a decrease in NOVA's stock price. The Overweight rating indicates a positive outlook on the company's fundamentals, but the significant cut in the price target might overshadow this optimism in the short term.